Pfenex (PFNX) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pfenex Reports First Quarter 2015 Results and Provides Business Update
May 14, 2015 8:02 AM EDTSAN DIEGO, May 14, 2015 /PRNewswire/ --Â Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the first quarter ended March 31, 2015 and provided a business update.
"The first quarter 2015 was very active for Pfenex, with our announcement in February of the collaboration with Hospira for our lead compound, PF582, a biosimilar candidate to Lucentis. As we have previously disclosed,... More
